drugset / Trial / NCT00868907

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

NCT00868907

Phase 1 Completed 101 enrolled Warner Chilcott Sanofi · collab
RandomizedCrossoverOpen-labelTreatment

Summary

Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2 and 3), 3 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1, 2 and 3), and exit procedures.

Timeline

Start
2009-03
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risedronate Small molecule 35 mg Oral

Indications

No indication recorded.